top of page

USFDA Med Dev Guidance: Medical Device User Fee Small Business Qualification and Determination

In July 2025, the USFDA published a revised guidance titled "Medical Device User Fee Small Business Qualification and Determination",which offers detailed instructions for industry, FDA staff, and foreign governments on how small businesses can qualify for reduced user fees or waivers under the Medical Device User Fee Amendments (MDUFA) program. This update replaces the 2018 guidance and reflects the FDA’s ongoing efforts to make regulatory pathways clearer and more accessible to innovators worldwide.


ree

Medical device user fees can be significant, especially for start-ups and small companies developing new devices. To encourage innovation, MDUFA allows businesses that qualify as small businesses to pay:

✅ Lower application fees

✅ A one-time waiver for the first premarket application/report fee

✅ A waiver of the annual establishment registration fee in cases of financial hardship

The new guidance explains exactly how to request these benefits — and what documentation is required.


Who can qualify

The guidance sets different thresholds for different types of fee relief:

Benefit

Definition of small business (incl. affiliates)

Notes

Reduced application fees

≤ $100 million in gross receipts/sales

Applies to PMAs, 510(k)s, De Novo, BLAs, and others

First premarket application/report fee waiver

≤ $30 million

Only once, for the first PMA/BLA/PDP/PMR

Registration fee waiver (financial hardship)

≤ $1 million

Applicant must also show financial hardship (e.g., bankruptcy)

Importantly, the definition of “affiliate” is broad: businesses under shared control must combine their revenue when calculating eligibility.


How to apply

The guidance explains step-by-step processes depending on whether your business is:

  • Headquartered in the U.S.

  • Headquartered abroad

  • A foreign affiliate of a U.S. firm

  • A national taxing authority supporting foreign applicants

For U.S. businesses:

✅ Complete a MDUFA Small Business Request (SBR) in the CDRH Portal

✅ Include your latest signed Federal (U.S.) income tax return and those of affiliates

✅ Obtain an Organization ID number (Org ID)

For foreign businesses:

✅ Use the MDUFA Foreign SBR form

✅ Have your national taxing authority complete the required certification, including official seal, revenues in local currency and USD, and exchange rate

✅ Submit via the CDRH Portal

For financial hardship waivers, applicants should also provide evidence of active bankruptcy and prior registration fee payment.


What are the benefits

If approved, a small business may:

  • Pay reduced fees for PMAs, BLAs, PDPs, 510(k)s, De Novo requests, annual reports, and more

  • Receive a one-time waiver for the first premarket application/report fee

  • Obtain a registration fee waiver (once) if paying the fee would cause financial hardship

FDA’s decision on small business qualification applies for one fiscal year only (October 1 – September 30). Businesses must apply annually to keep benefits.


Process improvements in the 2025 update

This version:

✅ Clarifies timelines and tax documentation

✅ Explains new submission process through the CDRH Portal

✅ Provides clearer guidance for foreign businesses and national taxing authorities

✅ Includes a helpful FAQs section covering common issues like affiliates, Org IDs, and tax extensions


For a detailed, procedural tips check this guidance document:

Comments


I Sometimes Send Newsletters

Thanks for submitting!

  • LinkedIn
  • Facebook
  • Twitter
  • Instagram

DISCLAIMER

The views expressed in this publication do not necessarily reflect the views of any guidance of government, health authority, it's purely my understanding. This Blog/Web Site is made available by a regulatory professional, is for educational purposes only as well as to give you general information and a general understanding of the pharmaceutical regulations, and not to provide specific regulatory advice. By using this blog site you understand that there is no client relationship between you and the Blog/Web Site publisher. The Blog/Web Site should not be used as a substitute for competent pharma regulatory advice and you should discuss from an authenticated regulatory professional in your state.  We have made every reasonable effort to present accurate information on our website; however, we are not responsible for any of the results you experience while visiting our website and request to use official websites.

bottom of page